Vascular Flashcards
Flame-shaped hemorrhages - where
track along the nerve fiber layer
dot/blot shaped hemorrhages - where
outer plexiform/inner nuclear layers
Central retinal artery - layers
intima (single layer of endothelium resting on a collagenous zone), internal elastic lamina, media (smooth muscle), adventitia (loose connective tissue)
Retinal arterioles - characteristic feature
internal elastic lamina is discontinuous
Exudates - where in the retina
outer plexiform layer
Microaneurysms - where in retina
in the inner capillary plexus (inner nuclear layer)
DME - which layers
between the outer plexiform and inner nuclear layers; later it may also involve the inner plexiform and nerve fibre layers
Cotton wool spots - where in the retina
within the nerve fibre layer. They are clinically evident only in the post-equatorial retina
BRVO - quadrant most commonly affected
superotemporal
Neovascularization following BRVO
8% of eyes by three years. NVE are more common than NVD
BRVO - FA
peripheral and macular ischaemia (capillary non-perfusion, staining of vessel walls, vessel ‘pruning’ – small branches failing to fill), haemorrhage and oedema with collateral vessels commonly forming in established cases. Venous filling is delayed
BRVO - treatment
• NVE or NVD - sector photocoagulation. • NVI - urgent sector PRP. •edema - antiVEGF/Intravitreal dexamethasone implant • If visual acuity remains 6/12 or worse after 3–6 months due to macular oedema that is associated with good central macular perfusion on FA, laser may be considered
Impending (partial) CRVO - FAF and FA
FAF may reveal a fern-like perivenular appearance, and FA generally demonstrates an impaired retinal circulation
Non-ischaemic CRVO - FAF
characteristic fern-like perivenular hypoautofluorescence due to masking of background signal by oedema
Non-ischaemic CRVO - FA
delayed arteriovenous transit time, masking by haemorrhage, usually good retinal capillary perfusion and some late leakage
Rubeosis iridis after ischaemic CRVO - %
50%
Retinal neovascularization after ischaemic CRVO - %
5% of eyes – much less commonly than with BRVO
ischaemic CRVO - FA
marked delay in arteriovenous transit time, masking by retinal haemorrhages, extensive areas of capillary non-perfusion and vessel wall staining and leakage
CME following CRVO - treatment
Treatment is generally indicated for VA worse than 6/9 and/or with significant central macular thickening (e.g. >250 μm) on OCT, but is unlikely to be of benefit if 6/120 or worse. ○ anti-VEGF ○ Intravitreal dexamethasone implant - (Ozurdex®) ○ Intravitreal triamcinolone ○ Laser photocoagulation. Although macular oedema is anatomically improved, laser is typically not beneficial for visual outcome, except in some younger patients